Role of Left Ventricular Biopsy in the Management of Heart Disease

ABSTRACT The prevalence of discrete subaortic stenosis (SAS) in adults with congenital heart disease (CHD) is 8 to 20%, with a male to female ratio of 2:1. Fixed SAS may be due to a discrete fibrous membrane, a muscular narrowing, or a combination of the two. The discrete form of fibromuscular SAS is most frequently encountered (90%), but the tunnel-type lesions are associated with a greater degree of stenosis. We report the case of a 16-year-old boy scheduled for double valve replacement (DVR) based on the preoperative echocardiographic report of rheumatic heart disease (RHD) with severe aortic stenosis (AS), severe aortic regurgitation (AR) and moderate mitral stenosis (MS), and moderate mitral regurgitation (MR) with severe left ventricular (LV) systolic dysfunction and LV apical clot. Preoperative transthoracic echocardiography (TTE) in the operation theater revealed discrete subaortic membrane (SAM) causing severe LV outflow tract obstruction (LVOTO). The patient underwent open heart surgery with resection of the discrete membrane and removal of apical clot. How to cite this article Bhat IH, Mandal B, Damodaran S, Kumar R. Role of Perioperative Echocardiography in Revision of Assessment: A Condition of Severe Aortic Stenosis leading to Left Ventricular Dysfunction and Apical Clot. J Perioper Echocardiogr 2017;5(2):77-81.

Download Full-text

Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice

Cardiosomatics ◽

10.26442/cs45087 ◽

2014 ◽

Vol 5 (1) ◽

pp. 56-62

Author(s):

A. V Barsukov ◽

D. V Glukhovskoy

Keyword(s):

Heart Disease ◽

Ischemic Heart Disease ◽

Left Ventricular Systolic Dysfunction ◽

Systolic Dysfunction ◽

Left Ventricular ◽

Ischemic Heart ◽

Modified Release ◽

Ventricular Systolic Dysfunction ◽

Chronic Ischemic Heart Disease

The paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with left ventricular systolic dysfunction. There described the clinical case with emphasis on possibility of inclusion in conservative treatment scheme of TMZ MB to poly morbid elderly patient with severe ischemic heart disease.

Download Full-text

Role of Early 2D Echocardiography in Patient with Acute Myocardial Infarction in Correlation with Electrocardiography and Clinical Presentation

MVP Journal of Medical Sciences ◽

10.18311/mvpjms/2014/v1/i2/837 ◽

2014 ◽

Vol 1 (2) ◽

pp. 51

Author(s):

Jitendra Kodilkar ◽

Mrunal Suresh Patil ◽

Neelima Chafekar ◽

Ashwinkumar More

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Heart Disease ◽

Clinical Presentation ◽

Health Centre ◽

Left Ventricular ◽

Prior History ◽

Killip Class ◽

2D Echocardiography

Introduction: Echocardiography is noninvasive, most frequently used usually the initial imaging test to evaluate all cardiovascular disease related to structural, functional, or hemodynamic abnormality of the heart or great vessels. The major advantage of echocardiography is the ability to obtain instantaneous real time image even in emergency units. The present study was undertaken to evaluate left ventricular function, extent of myocardium involved and complications of acute myocardial infarction by 2D ECHO, to correlate these findings with ECG and clinical presentation, and to assess the role of 2D ECHO in management and prognosis of patients with acute myocardial infarction. Materials and Methods: The present study was conducted on patients visiting our tertiary health centre, Nasik over a period of 2 years. 55 patients were included in the study. Patients with prior history of acute myocardial infarction, valvular heart disease, cardiomyopathy, cardiac surgery, congenital heart disease and non ST elevation MI were not included in the study. Patients were classified as per Killip classification and 2D ECHO was performed on the patients within 24 hours of admission. The findings of which were correlated with clinical and ECG findings. Results: Of 55 patients studied it was found that MI had male preponderance with hypertension as major risk factor. Also, the severity of the infarction increased with the increase in the Killip class. Mean ejection fraction was also observed to be decreasing in patients with increase in severity of the infarction. Conclusion: 2D ECHO performed within 24 hours of admission helps the clinician to predict and diagnose complications in patients with acute MI and take proper steps in the management of the patient.

Download Full-text

Modern opportunities for optimising the treatment of patients with coronary heart disease and arterial hypertension: role of zofenopril

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2012-4-85-92 ◽

2012 ◽

Vol 11 (4) ◽

pp. 85-92

Author(s):

A. G. Evdokimova ◽

V. V. Evdokimov ◽

N. V. Leonenko ◽

A. V. Smetanin

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Arterial Hypertension ◽

Clinical Case ◽

Ace Inhibitor ◽

Cardiovascular Death ◽

Left Ventricular ◽

Antihypertensive Activity ◽

Acute Mi

The wide prevalence (82%) of coronary heart disease (CHD) in combination with arterial hypertension (AH), as well as its initiating role in the development of fatal complications, such as myocardial infarction (MI) or heart failure, emphasise the need for the choice of optimal ACE inhibitors with organ-protective characteristics. This paper presents a literature review on the effectiveness of a SH-containing ACE inhibitor zofenopril in patients with CHD and AH, in terms of its anti-anginal and antihypertensive activity. The authors summarise the results of the international SMILE studies which included patients after acute MI. It was demonstrated that zofenopril therapy is associated with reduced combined incidence of cardiovascular death or cardiovascular hospitalisation, and is also safe in the acute post-MI period. In patients with preserved left ventricular function, zofenopril reduced the incidence of angina attacks and arrhythmias of coronary genesis, as well as improved exercise capacity. A clinical case of zofenopril therapy, as a part of a complex treatment regimen, is also presented.

Download Full-text

What is the role of cardiac PET in patients with ischaemic heart disease and significant left ventricular dysfunction?

European Heart Journal ◽

10.1053/euhj.2001.2761 ◽

2001 ◽

Vol 22 (18) ◽

pp. 1629-1631 ◽

Cited By ~ 1

Author(s):

A Maes

Keyword(s):

Heart Disease ◽

Ischaemic Heart Disease ◽

Left Ventricular Dysfunction ◽

Ventricular Dysfunction ◽

Left Ventricular ◽

Cardiac Pet

Download Full-text

Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies

Seminars in Thrombosis and Hemostasis ◽

10.1055/s-0039-1692702 ◽

2019 ◽

Vol 45 (05) ◽

pp. 468-477 ◽

Cited By ~ 6

Author(s):

Antonella Tufano ◽

Matteo Nicola Dario Di Minno ◽

Anna Guida ◽

Maria Lembo ◽

Giovanni Di Minno ◽

...

Keyword(s):

Heart Disease ◽

Antiphospholipid Syndrome ◽

Cardiac Imaging ◽

High Titer ◽

Left Ventricular ◽

Immunoglobulin M ◽

Pregnancy Morbidity ◽

Heart Involvement ◽

Cardiac Manifestations

AbstractAntiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies, vascular thrombosis (venous, arterial, or small vessels), and/or pregnancy morbidity. Diagnosis of APS is based on the presence of at least one clinical criterion (thrombotic events or pregnancy morbidity) and at least one of the laboratory criteria (persistently medium/high titer immunoglobulin G [IgG]/immunoglobulin M [IgM] anticardiolipin antibodies, and/or medium/high titer IgG/IgM anti-β2-glycoprotein I antibodies, and/or a positive lupus anticoagulant test), confirmed after repetition at least 12 weeks apart. The clinical spectrum of APS encompasses additional (extracriteria) clinical manifestations, including cardiac diseases. Heart involvement may become evident as a consequence of direct (autoimmune-mediated) or indirect (thrombosis) mechanisms, and include valve heart disease (vegetations and/or thickening associated with functional abnormalities) and intracardiac thrombosis, coronary, and vascular accelerated atherosclerosis, along with ischemic heart disease. APS can also cause pulmonary arterial hypertension, left ventricular dysfunction, and heart failure. This review describes the major cardiac manifestations of APS and illustrates the role of cardiac imaging for diagnosing subclinical and overt heart involvement and addressing management of these patients. The possible role of therapeutic strategies in cardiac manifestations of APS is also discussed.

Download Full-text